Martina Viggiani
Overview
Explore the profile of Martina Viggiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parola S, Oing C, Rescigno P, Feliciano S, Carlino F, Pompella L, et al.
Front Genet
. 2024 Dec;
15:1480417.
PMID: 39678373
Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease....
2.
DArienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M, et al.
EClinicalMedicine
. 2023 Aug;
62:102113.
PMID: 37554126
Antibody-drug conjugates (ADCs) represent a novel and evolving class of antineoplastic agents, constituted by monoclonal antibody linked to biologically active drugs, delivering cytotoxic compounds at the tumor site, reducing the...
3.
Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, et al.
Clin Genitourin Cancer
. 2021 May;
19(5):e286-e298.
PMID: 33958297
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival...
4.
Schettini F, De Santo I, Rea C, Viggiani M, Buono G, De Angelis C, et al.
Mol Clin Oncol
. 2020 Apr;
12(5):456-460.
PMID: 32257203
Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line...
5.
PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis
Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, et al.
Arch Gynecol Obstet
. 2019 Mar;
299(6):1511-1524.
PMID: 30915635
Purpose: Rates of progression of endometrial hyperplasia (EH) to endometrial cancer (EC) are highly variable. Among several prognostic markers, PTEN has been recommended by ESMO-ESGO-ESTRO to identify premalignant EH. However,...